Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04659603 |
|
Recruitment Status :
Recruiting
First Posted : December 9, 2020
Last Update Posted : May 3, 2023
|
Sponsor:
Sanofi
Information provided by (Responsible Party):
Sanofi
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Primary Objective:
- For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with gemcitabine in metastatic pancreatic adenocarcinoma (mPAC)
- For Cohort C Part 1: Confirmation of the recommended tusamitamab ravtansine dose when administered in combination with gemcitabine
Secondary Objectives:
- To assess the safety and tolerability of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine
- To assess other efficacy parameters of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine
- To assess the immunogenicity of tusamitamab ravtansine
- To assess the pharmacokinetics (PK) of tusamitamab ravtansine and gemcitabine when given in combination
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer Metastatic Pancreatic Carcinoma Metastatic | Drug: tusamitamab ravtansine Drug: Gemcitabine | Phase 2 |
The expected duration of study intervention for participants may vary, based on progression date and the cohort; median expected duration of study per participant is estimated at 8 months for Cohort A/C and 6 months for Cohort B (up to 1 month for screening, a median of 4 or 2 months for treatment in Cohort A/C and Cohort B respectively, a median of 1 month for EOT, and follow-up visit 90 days after the last IMP administration).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 94 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors |
| Actual Study Start Date : | March 29, 2021 |
| Estimated Primary Completion Date : | July 9, 2024 |
| Estimated Study Completion Date : | January 13, 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Breast cancer
Drug Information available for:
Gemcitabine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort A metastatic breast cancer (mBC)
tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
|
Drug: tusamitamab ravtansine
Pharmaceutical form:Concentrated solution for IV; Route of administration: IV infusion Other Name: SAR408701 |
|
Experimental: Cohort B metastatic pancreatic adenocarcinoma (mPAC)
tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
|
Drug: tusamitamab ravtansine
Pharmaceutical form:Concentrated solution for IV; Route of administration: IV infusion Other Name: SAR408701 |
|
Experimental: Cohort C Metastatic pancreatic adenocarcinoma (mPAC)
tusamitamab ravtansine every 2 weeks combined with gemcitabine on Day 1, Day 8 and Day 15 every 4 weeks administered via intravenous infusion (IV)
|
Drug: tusamitamab ravtansine
Pharmaceutical form:Concentrated solution for IV; Route of administration: IV infusion Other Name: SAR408701 Drug: Gemcitabine Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion; Route of administration: IV infusion |
Primary Outcome Measures :
- Objective Response Rate (ORR)- Cohort A, Cohort B, and Cohort C Part 2 [ Time Frame: Baseline up to 6 months after the last patient treated have 2 postbaseline tumor assessments ]Objective Response Rate (ORR) of tusamitamab ravtansine in mBC and tusamitamab ravtansine monotherapy and in combination with gemcitabine in mPAC, defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
- Incidence of dose-limiting toxicites (DLTs)- Cohort C Part 1 [ Time Frame: 28 days (Cycle 1) ]Incidence of dose-limiting toxicites (DLTs) in the 28 Day DLT observation period (Cycle 1)
Secondary Outcome Measures :
- Incidence of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [ Time Frame: Baseline up to 90 days after the last study treatment administration ]TEAEs, SAEs and laboratory abnormalities according to NCI CTCAE v5.0.
- Progression free survival (PFS) [ Time Frame: Baseline up to 6 months after the last patient treated have 2 postbaseline tumor assessments ]PFS defined as the time from the date of first tusamitamab ravtansine administration to the date of the first documented disease progression or death due to any cause, whichever comes first.
- Disease control rate (DCR) [ Time Frame: Baseline up to 6 months after the last patient treated have 2 postbaseline tumor assessments ]DCR defined as the percentage of participants who have achieved CR, PR or stable disease as per RECIST v1.1.
- Duration of Response (DOR) [ Time Frame: Baseline up to 6 months after the last patient treated have 2 postbaseline tumor assessments ]DOR defined as the time from first documented evidence of CR or PR until progressive disease determined per RECIST v1.1 or death from any cause, whichever occurs first.
- Incidence of participants with anti-therapeutic antibodies (ATAs) against tusamitamab ravtansine [ Time Frame: Baseline until one month after last patient last treatment ]Incidence of participants with anti-therapeutic antibodies (ATAs) against tusamitamab ravtansine.
- Maximum concentration observed after infusion (Cmax) of tusamitamab ravtansine [ Time Frame: After 1st administration at Cycle 1 Day 1 (1 Cycle = 28 days) ]Pharmacokinetic parameter of tusamitamab ravtansine.
- Area under the plasma concentration versus time curve from time 0 to 14 days (AUC0-14d) [ Time Frame: After 1st administration at Cycle 1 Day 1 (1 Cycle = 28 days) ]Pharmacokinetic parameter of tusamitamab ravtansine. AUC0-14d calculated using the trapezoidal method.
- Total body clearance (CL) [ Time Frame: After 1st administration at Cycle 1 Day 1 (1 Cycle = 28 days) ]Pharmacokinetic parameter of gemcitabine.
- Maximum concentration observed after infusion (Cmax) of gemcitabine metabolite [ Time Frame: After 1st administration at Cycle 1 Day 1 (1 Cycle = 28 days) ]Pharmacokinetic parameter of gemcitabine metabolite.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participant must be at least 18 years of age
- Participants with at least one measurable lesion according to the RECIST v1.1 criteria that has not been irradiated (ie, newly arising lesions in previously irradiated areas are accepted).
- Participants with ECOG performance status 0 to 1.
- Evidence of metastatic disease.
- Expression of CEACAM 5 by centrally assessed IHC assay.
- Male and female participants willing to comply with contraceptive use consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Cohort A: mBC
- Histological or cytologic diagnosis of breast cancer.
- Have received at least 2 prior cytotoxic chemotherapy regimens for non-TNBC tumor type or at least 1 for TNBC tumor type but not more than 4 in the locally recurrent or metastatic setting.
Cohorts B and C: mPAC
- Have confirmed diagnosis of pancreatic ductal adenocarcinoma.
Cohort B: mPAC:
- Have documented radiographic progression or documented intolerance after at least 1 prior systemic chemotherapy line which included either gemcitabine (or relapsed within 6 months of completion of gemcitabine adjuvant therapy) or a 5-fluorouracil based regimen (including capecitabine) but no more than 2 prior chemotherapy lines for locally advanced/metastatic disease.
Cohort C: mPAC
- Have documented radiographic progression or documented intolerance after 1st line fluoropyrimidine-containing chemotherapy (or relapsed within 6 months of completion of chemotherapy as adjuvant therapy) for locally advanced/metastatic disease.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Medical condition requiring concomitant administration of a medication with a narrow therapeutic window, that is metabolized by cytochrome P450 (CYP450), and for which a dose reduction cannot be considered.
- Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before the first administration of study intervention.
- Life expectancy less than 3 months.
- Untreated brain metastases or history of leptomeningeal disease.
- Significant concomitant illness
- History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
- History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or active hepatitis A, B or C infection.
- Non-resolution of any prior treatment-related toxicity to <Grade 2 according to NCI CTCAE v5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy (HRT).
- Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy.
- Use of contact lenses. Participants using contact lenses who are not willing to stop wearing them for the duration of the study intervention are excluded.
- Concurrent treatment with any other anti cancer therapy.
- Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for prior antitumor therapy (chemotherapy, targeted agents, immunotherapy and radiotherapy, or any investigational treatment).
- Any prior therapy targeting CEACAM5.
- Prior maytansinoid DM4 treatment (ADC).
- Any major surgery within the preceding 2 weeks of the first study intervention administration.
- Previous enrollment in this study or current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
- Poor renal function
- Poor hepatic function
- Poor bone marrow function
Cohort C: mPAC
- Any previous systemic therapy with taxane or gemcitabine (for Cohort C only).
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04659603
Contacts
| Contact: Trial Transparency email recommended (Toll free number for US & Canada) | 800-633-1610 ext option 6 | Contact-US@sanofi.com |
Locations
Show 29 study locations
Sponsors and Collaborators
Sanofi
Investigators
| Study Director: | Clinical Sciences & Operations | Sanofi |
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT04659603 |
| Other Study ID Numbers: |
ACT16432 2020-003096-18 ( EudraCT Number ) U1111-1244-1644 ( Registry Identifier: ICTRP ) |
| First Posted: | December 9, 2020 Key Record Dates |
| Last Update Posted: | May 3, 2023 |
| Last Verified: | May 2, 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Gemcitabine |
Maytansine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antineoplastic Agents, Phytogenic Tubulin Modulators Antimitotic Agents Mitosis Modulators |